We are happy and proud to announce the acquisition of Organix, a US-based provider of high-quality organic chemistry services. The company is dedicated to the discovery and preclinical stage of the drug-discovery value chain, with a focus on lipids and small molecules. Organix has 47 employees, the majority of which have a PhD in chemistry, and is based in Woburn, in the Boston, MA, area. Its revenue is mainly generated from the sale of specialized and complex organic chemistry research services to biopharma clients.
Symeres and Organix are highly complementary, and the combination unlocks significant strategic value. Organix represents a high-quality foothold into the US market, where Symeres already generates about 40% of its revenues. Furthermore, Organix broadens the Symeres drug-discovery offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines. Organix’s impressive client list includes some of the world’s leading biopharma companies, many based in the Boston biopharma community. Organix management will remain unchanged; the company is led by Dr. Anu Mahadevan, CEO, and Dr. Paul Blundell.
Symeres CEO Eelco Ebbers is very pleased to quickly integrate Organix into the Symeres group: “Organix is widely known as being highly innovative and an expert organic chemistry services provider that is able to solve complex projects for top-tier clients globally. Joining forces represents a fantastic opportunity for us to expand our drug-discovery-capability offering and provide an exceptional high-quality foothold into the US market.”
As the majority shareholder in Symeres, Keensight Capital has worked together with the management team of the two companies to facilitate this combination. Amit Karna, Partner at Keensight Capital, comments: “We are delighted to support Symeres in this exciting acquisition of Organix. We are certain that the resulting business will create a truly differentiated transatlantic offering for the biopharma industry, with significant expertise in molecule design, synthesis, and early-stage clinical manufacturing. Moreover, the scientific and cultural fit of the two organizations could not be more perfect, and we are excited to see what the management teams will achieve together.”
View the official press release here.